The European Medicines Agency (EMA) has published its regulatory science strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines. 

It comes in response to the acceleration of the pace of innovation and the need for regulators to be ready to support the development of increasingly complex medicines that combine different technologies. 

The ongoing Covid-19 pandemic underlines the need for rapid and close engagement of all stakeholders and partners involved in the development and supervision of medicines in the European Union and globally, which is one of the fundamental principles of this strategy. 

The five key goals are:

• Catalysing the integration of science and technology in medicines development
• Driving collaborative evidence generation improving the scientific quality of evaluations
• Advancing patient-centred access to medicines in partnership with healthcare systems
• Addressing emerging health threats and availability/therapeutic challenges
• Enabling and leveraging research and innovation in regulatory science

More information